Heart failure of very rare aetiology-haemochromatosis Type 3: a case report.

IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
European Heart Journal: Case Reports Pub Date : 2024-11-29 eCollection Date: 2024-12-01 DOI:10.1093/ehjcr/ytae637
Aistė Montvilaitė-Laurinavičienė, Rūta Dirsienė, Gintarė Neverauskaitė-Piliponienė, Audra Banišauskaitė, Marius Šukys, Gintarė Šakalytė, Eglė Ereminienė
{"title":"Heart failure of very rare aetiology-haemochromatosis Type 3: a case report.","authors":"Aistė Montvilaitė-Laurinavičienė, Rūta Dirsienė, Gintarė Neverauskaitė-Piliponienė, Audra Banišauskaitė, Marius Šukys, Gintarė Šakalytė, Eglė Ereminienė","doi":"10.1093/ehjcr/ytae637","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Haemochromatosis is a pathological condition characterized by the accumulation of iron in parenchymal organs, leading to toxic damage and dysfunction. Cardiac haemochromatosis represents one of the rare causes of severe heart failure (HF) that can be potentially prevented with targeted treatment.</p><p><strong>Case summary: </strong>We present the case of a 41-year-old female who was hospitalized for decompensated HF. Echocardiography revealed severe systolic dysfunction with a phenotype of dilated cardiomyopathy, accompanied by secondary moderate mitral regurgitation and severe tricuspid regurgitation (TR). To differentiate potential causes of HF, coronary angiography, cardiac magnetic resonance imaging (MRI), and endomyocardial biopsy were performed. Based on clinical findings, laboratory results, cardiac MRI, and endomyocardial biopsy data, a diagnosis of haemochromatosis was confirmed, and mutations in the <i>TFR2</i> gene, responsible for haemochromatosis Type 3, were identified. The patient was treated in accordance with the latest European Society of Cardiology HF guidelines, and specific treatment for haemochromatosis, including therapeutic phlebotomy and iron chelation therapy, was initiated, resulting in a significant positive outcome.</p><p><strong>Discussion: </strong>Investigating the aetiology of HF is essential, as even rare causes can be identified, and specific treatments are available that significantly improve prognosis and survival.</p>","PeriodicalId":11910,"journal":{"name":"European Heart Journal: Case Reports","volume":"8 12","pages":"ytae637"},"PeriodicalIF":0.8000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647590/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal: Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ehjcr/ytae637","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Haemochromatosis is a pathological condition characterized by the accumulation of iron in parenchymal organs, leading to toxic damage and dysfunction. Cardiac haemochromatosis represents one of the rare causes of severe heart failure (HF) that can be potentially prevented with targeted treatment.

Case summary: We present the case of a 41-year-old female who was hospitalized for decompensated HF. Echocardiography revealed severe systolic dysfunction with a phenotype of dilated cardiomyopathy, accompanied by secondary moderate mitral regurgitation and severe tricuspid regurgitation (TR). To differentiate potential causes of HF, coronary angiography, cardiac magnetic resonance imaging (MRI), and endomyocardial biopsy were performed. Based on clinical findings, laboratory results, cardiac MRI, and endomyocardial biopsy data, a diagnosis of haemochromatosis was confirmed, and mutations in the TFR2 gene, responsible for haemochromatosis Type 3, were identified. The patient was treated in accordance with the latest European Society of Cardiology HF guidelines, and specific treatment for haemochromatosis, including therapeutic phlebotomy and iron chelation therapy, was initiated, resulting in a significant positive outcome.

Discussion: Investigating the aetiology of HF is essential, as even rare causes can be identified, and specific treatments are available that significantly improve prognosis and survival.

病因非常罕见的心力衰竭--血色素沉着病 3 型:病例报告。
背景:血色素沉着病是一种病理状态,其特点是铁在实质器官中蓄积,导致毒性损伤和功能障碍。心脏血色病是导致严重心力衰竭(HF)的罕见病因之一,有可能通过针对性治疗加以预防。病例摘要:本病例为一名因失代偿性心力衰竭住院的 41 岁女性。超声心动图显示,患者存在严重的收缩功能障碍,表现为扩张型心肌病,并伴有继发性中度二尖瓣反流和严重三尖瓣反流(TR)。为了区分心房颤动的潜在病因,医生进行了冠状动脉造影、心脏磁共振成像(MRI)和心内膜活检。根据临床发现、实验室结果、心脏磁共振成像和心内膜活检数据,确诊为血色沉着病,并确定了导致血色沉着病 3 型的 TFR2 基因突变。根据最新的欧洲心脏病学会高血压指南对患者进行了治疗,并启动了血色素沉着病的特殊治疗,包括治疗性抽血疗法和铁螯合疗法,取得了显著的疗效:讨论:调查心房颤动的病因至关重要,因为即使是罕见的病因也能被识别出来,而且特定的治疗方法可显著改善预后和存活率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Heart Journal: Case Reports
European Heart Journal: Case Reports Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.30
自引率
10.00%
发文量
451
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信